EGFR and neoplasm: Haas-Kogan et al. showed, based upon a tissue analysis, that erlotinib has a significantly better effect on tumours expressing high levels of EGFR and low levels of phosphorylated protein kinase B (AKT) compared to tumours with low EGFR levels and high levels of phosphorylated AKT [31,32].